Synaptogenix Inc (SNPX)

[XenaLives]

Overview - Research Study Summary

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s Disease
Purpose

This research study is being conducted to determine how safe and tolerable bryostatin is and how well it works when it is given to patients who have moderately severe to severe Alzheimer’s disease. Patients will be assigned to 1 of the following 3 groups: (1) a bryostatin low-dose group, (2) a bryostatin high-dose group, and (3) a placebo group. A placebo is a study drug look-alike, but it contains no active study drug ingredients (like a sugar pill).

Study drug or placebo will be given via an infusion in your vein that will last about 45 minutes. Study staff will monitor the patient’s vital signs and watch for any side effects during the infusion. In research studies, we do not know which dose is best. To find out, we need to compare different doses. The results are compared to see if one dose is better than another.
To Learn more

Review research study eligibility criteria »
Read more benefits and details for the research study »
Contact information for clinical study »

CW ID: 219044
Date Last Changed: September 28, 2016

https://www.centerwatch.com/clinical-trials/listings/studydetails.aspx?StudyID=219044